{"DataElement":{"publicId":"6042938","version":"1","preferredName":"Disease or Disorder Positron Emission Tomography Metabolic Response Status Lugano Lymphoma Response Classification Type","preferredDefinition":"A description of the positron emission tomography metabolic lugano lymphoma response disease status.","longName":"6042911v1.0:6042901v1.0","context":"NHLBI","contextVersion":"1","DataElementConcept":{"publicId":"6042911","version":"1","preferredName":"Disease or Disorder Positron Emission Tomography Metabolic Response Status","preferredDefinition":"Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function._A technique for measuring the gamma radiation produced by collisions of electrons and positrons (anti-electrons) within living tissue. In positron emission tomography (PET), a subject is given a dose of a positron-emitting radionuclide attached to a metabolically active substance (for example, 2-fluoro-2-deoxy-D-glucose (FDG), which is similar to a naturally occurring sugar, glucose, with the addition of a radioactive fluorine atom). When living tissue containing the positron emitter is bombarded by electrons, gamma radiation produced by collisions of electrons and positrons is detected by a scanner, revealing in fine detail the tissue location of the metabolically-active substance administered._An evaluation of the metabolic response of the disease to the therapy._A condition or state at a particular time.","longName":"2404658v1.0:6042909v1.0","context":"NHLBI","contextVersion":"1","ObjectClass":{"publicId":"2404658","version":"1","preferredName":"Diseases and Disorders","preferredDefinition":"A definite pathologic process with a characteristic set of signs and symptoms. It may affect the whole body or any of its parts, and its etiology, pathology, and prognosis may be known or unknown.","longName":"C2991","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Disease or Disorder","conceptCode":"C2991","definition":"Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"005AD6E5-0651-6A35-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-09-09","endDate":null,"createdBy":"PWEST","dateCreated":"2005-09-09","modifiedBy":"ONEDATA","dateModified":"2005-09-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"6042909","version":"1","preferredName":"Positron Emission Tomography Metabolic Response Status","preferredDefinition":"A technique for measuring the gamma radiation produced by collisions of electrons and positrons (anti-electrons) within living tissue. In positron emission tomography (PET), a subject is given a dose of a positron-emitting radionuclide attached to a metabolically active substance (for example, 2-fluoro-2-deoxy-D-glucose (FDG), which is similar to a naturally occurring sugar, glucose, with the addition of a radioactive fluorine atom). When living tissue containing the positron emitter is bombarded by electrons, gamma radiation produced by collisions of electrons and positrons is detected by a scanner, revealing in fine detail the tissue location of the metabolically-active substance administered.:An evaluation of the metabolic response of the disease to the therapy.:A condition or state at a particular time.","longName":"C17007:C123623:C25688","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Positron Emission Tomography","conceptCode":"C17007","definition":"A technique for measuring the gamma radiation produced by collisions of electrons and positrons (anti-electrons) within living tissue. In positron emission tomography (PET), a subject is given a dose of a positron-emitting radionuclide attached to a metabolically active substance (for example, 2-fluoro-2-deoxy-D-glucose (FDG), which is similar to a naturally occurring sugar, glucose, with the addition of a radioactive fluorine atom). When living tissue containing the positron emitter is bombarded by electrons, gamma radiation produced by collisions of electrons and positrons is detected by a scanner, revealing in fine detail the tissue location of the metabolically-active substance administered.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Metabolic Response","conceptCode":"C123623","definition":"An evaluation of the metabolic response of the disease to the therapy.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Status","conceptCode":"C25688","definition":"A condition or state at a particular time.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6052CFA3-3C28-2FE0-E053-F662850AB5B8","latestVersionIndicator":"Yes","beginDate":"2017-12-14","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-12-14","modifiedBy":"ONEDATA","dateModified":"2017-12-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008551","version":"1","preferredName":"Assessments","preferredDefinition":"evaluations of the patient and the patient's disease.","longName":"ASSESS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22DA727-6718-5A2D-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"6052CFA3-3C39-2FE0-E053-F662850AB5B8","latestVersionIndicator":"Yes","beginDate":"2017-12-14","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-12-14","modifiedBy":"NYCHM","dateModified":"2018-02-12","changeDescription":".","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"6042901","version":"1","preferredName":"Positron Emission Tomography Lugano Lymphoma Response Classification Type","preferredDefinition":"A technique for measuring the gamma radiation produced by collisions of electrons and positrons (anti-electrons) within living tissue. In positron emission tomography (PET), a subject is given a dose of a positron-emitting radionuclide attached to a metabolically active substance (for example, 2-fluoro-2-deoxy-D-glucose (FDG), which is similar to a naturally occurring sugar, glucose, with the addition of a radioactive fluorine atom). When living tissue containing the positron emitter is bombarded by electrons, gamma radiation produced by collisions of electrons and positrons is detected by a scanner, revealing in fine detail the tissue location of the metabolically-active substance administered._A lymphoma response criteria system developed at the 11th International Conference on Malignant Lymphoma (ICML) in Lugano, Switzerland, June 2011._Something distinguishable as an identifiable class based on common qualities.","longName":"6042901v1.0","context":"NHLBI","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"60","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Continued complete remission (CCR)","valueDescription":"Continued Lugano Lymphoma Response Classification Complete Remission by PET","ValueMeaning":{"publicId":"6042902","version":"1","preferredName":"Continued Lugano Lymphoma Response Classification Complete Remission by PET","longName":"6042902","preferredDefinition":"Remain in force or carry on without letup; keep or maintain in unaltered condition; exist in time or space without stop or interruption.: A score of 1, 2, or 3 on a 5-point PET scale in nodal or extranodal sites with or without a residual mass. No evidence of FDG-avid disease in the marrow.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Continue","conceptCode":"C53279","definition":"Remain in force or carry on without letup; keep or maintain in unaltered condition; exist in time or space without stop or interruption.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Lugano Lymphoma Response Classification Complete Remission by PET","conceptCode":"C142795","definition":"A score of 1, 2, or 3 on a 5-point PET scale in nodal or extranodal sites with or without a residual mass. No evidence of FDG-avid disease in the marrow.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"605291C2-37AB-41C5-E053-F662850AB413","latestVersionIndicator":"Yes","beginDate":"2017-12-14","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-12-14","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"605291C2-37C4-41C5-E053-F662850AB413","beginDate":"2017-12-14","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-12-14","modifiedBy":"ONEDATA","dateModified":"2017-12-14","deletedIndicator":"No"},{"value":"Unknown","valueDescription":"Unknown","ValueMeaning":{"publicId":"2960664","version":"1","preferredName":"Unknown","longName":"2960664","preferredDefinition":"Not known, not observed, not recorded, or refused.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Unknown","conceptCode":"C17998","definition":"Not known, observed, recorded; or reported as unknown by the data contributor.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"78485FBD-4C65-D67B-E040-BB89AD432E0E","latestVersionIndicator":"Yes","beginDate":"2009-11-13","endDate":null,"createdBy":"AHMEDS","dateCreated":"2009-11-13","modifiedBy":"KUMMEROA","dateModified":"2023-12-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"605291C2-37CE-41C5-E053-F662850AB413","beginDate":"2017-12-14","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-12-14","modifiedBy":"ONEDATA","dateModified":"2017-12-14","deletedIndicator":"No"},{"value":"Not assessed","valueDescription":"NOT ASSESSED","ValueMeaning":{"publicId":"2559594","version":"1","preferredName":"NOT ASSESSED","longName":"2559594","preferredDefinition":"Indicates that an assessment was not performed.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Not Assessed","conceptCode":"C139527","definition":"Indicates that an assessment was not performed.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B5D7-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"MMADDINENI","dateModified":"2024-02-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"605291C2-37D8-41C5-E053-F662850AB413","beginDate":"2017-12-14","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-12-14","modifiedBy":"ONEDATA","dateModified":"2017-12-14","deletedIndicator":"No"},{"value":"Progressive disease (PD)","valueDescription":"Lugano Lymphoma Response Classification Progressive Disease by PET","ValueMeaning":{"publicId":"6042903","version":"1","preferredName":"Lugano Lymphoma Response Classification Progressive Disease by PET","longName":"6042903","preferredDefinition":"A score of 4 or 5 on a 5-point PET scale with an increase in intensity of uptake from baseline and/or new FDG-avid foci consistent with lymphoma at interim or end of treatment assessment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lugano Lymphoma Response Classification Progressive Disease by PET","conceptCode":"C142798","definition":"A score of 4 or 5 on a 5-point PET scale with an increase in intensity of uptake from baseline and/or new FDG-avid foci consistent with lymphoma at interim or end of treatment assessment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"605291C2-37E4-41C5-E053-F662850AB413","latestVersionIndicator":"Yes","beginDate":"2017-12-14","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-12-14","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"605291C2-37FD-41C5-E053-F662850AB413","beginDate":"2017-12-14","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-12-14","modifiedBy":"ONEDATA","dateModified":"2017-12-14","deletedIndicator":"No"},{"value":"No response (NR) / Stable disease (SD)","valueDescription":"Lugano Lymphoma Response Classification No Response/Stable Disease by PET","ValueMeaning":{"publicId":"6042904","version":"1","preferredName":"Lugano Lymphoma Response Classification No Response/Stable Disease by PET","longName":"6042904","preferredDefinition":"A score of 4 or 5 on a 5-point PET scale with no significant change in FDG uptake from baseline, at interim or end of treatment. No change in the bone marrow from baseline.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lugano Lymphoma Response Classification No Response/Stable Disease by PET","conceptCode":"C142797","definition":"A score of 4 or 5 on a 5-point PET scale with no significant change in FDG uptake from baseline, at interim or end of treatment. No change in the bone marrow from baseline.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"605291C2-3809-41C5-E053-F662850AB413","latestVersionIndicator":"Yes","beginDate":"2017-12-14","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-12-14","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"605291C2-3822-41C5-E053-F662850AB413","beginDate":"2017-12-14","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-12-14","modifiedBy":"ONEDATA","dateModified":"2017-12-14","deletedIndicator":"No"},{"value":"Partial remission (PR)","valueDescription":"Lugano Lymphoma Response Classification Partial Remission by PET","ValueMeaning":{"publicId":"6042905","version":"1","preferredName":"Lugano Lymphoma Response Classification Partial Remission by PET","longName":"6042905","preferredDefinition":"A score of 4 or 5 on a 5-point PET scale with reduced uptake compared with baseline and residual mass(es) of any size. Residual uptake higher than uptake in normal marrow but reduced compared to baseline.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lugano Lymphoma Response Classification Partial Remission by PET","conceptCode":"C142796","definition":"A score of 4 or 5 on a 5-point PET scale with reduced uptake compared with baseline and residual mass(es) of any size. Residual uptake higher than uptake in normal marrow but reduced compared to baseline.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"605291C2-382E-41C5-E053-F662850AB413","latestVersionIndicator":"Yes","beginDate":"2017-12-14","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-12-14","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"605291C2-3847-41C5-E053-F662850AB413","beginDate":"2017-12-14","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-12-14","modifiedBy":"ONEDATA","dateModified":"2017-12-14","deletedIndicator":"No"},{"value":"Complete remission (CR)","valueDescription":"Lugano Lymphoma Response Classification Complete Remission by PET","ValueMeaning":{"publicId":"6042906","version":"1","preferredName":"Lugano Lymphoma Response Classification Complete Remission by PET","longName":"6042906","preferredDefinition":"A score of 1, 2, or 3 on a 5-point PET scale in nodal or extranodal sites with or without a residual mass. No evidence of FDG-avid disease in the marrow.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lugano Lymphoma Response Classification Complete Remission by PET","conceptCode":"C142795","definition":"A score of 1, 2, or 3 on a 5-point PET scale in nodal or extranodal sites with or without a residual mass. No evidence of FDG-avid disease in the marrow.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"605291C2-3853-41C5-E053-F662850AB413","latestVersionIndicator":"Yes","beginDate":"2017-12-14","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-12-14","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"605291C2-386C-41C5-E053-F662850AB413","beginDate":"2017-12-14","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-12-14","modifiedBy":"ONEDATA","dateModified":"2017-12-14","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008550","version":"1","preferredName":"Disease Response","preferredDefinition":"the response criteria (includes RECIST and others) and associated documentation of disease.","longName":"DZ_RESP","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22C0651-216B-5273-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"6042900","version":"1","preferredName":"Positron Emission Tomography Lugano Lymphoma Response Classification Type","preferredDefinition":"A technique for measuring the gamma radiation produced by collisions of electrons and positrons (anti-electrons) within living tissue. In positron emission tomography (PET), a subject is given a dose of a positron-emitting radionuclide attached to a metabolically active substance (for example, 2-fluoro-2-deoxy-D-glucose (FDG), which is similar to a naturally occurring sugar, glucose, with the addition of a radioactive fluorine atom). When living tissue containing the positron emitter is bombarded by electrons, gamma radiation produced by collisions of electrons and positrons is detected by a scanner, revealing in fine detail the tissue location of the metabolically-active substance administered.:A lymphoma response criteria system developed at the 11th International Conference on Malignant Lymphoma (ICML) in Lugano, Switzerland, June 2011.:Something distinguishable as an identifiable class based on common qualities.","longName":"C17007:C142790:C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Positron Emission Tomography","conceptCode":"C17007","definition":"A technique for measuring the gamma radiation produced by collisions of electrons and positrons (anti-electrons) within living tissue. In positron emission tomography (PET), a subject is given a dose of a positron-emitting radionuclide attached to a metabolically active substance (for example, 2-fluoro-2-deoxy-D-glucose (FDG), which is similar to a naturally occurring sugar, glucose, with the addition of a radioactive fluorine atom). When living tissue containing the positron emitter is bombarded by electrons, gamma radiation produced by collisions of electrons and positrons is detected by a scanner, revealing in fine detail the tissue location of the metabolically-active substance administered.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Lugano Lymphoma Response Classification","conceptCode":"C142790","definition":"A lymphoma response criteria system developed at the 11th International Conference on Malignant Lymphoma (ICML) in Lugano, Switzerland, June 2011.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"605291C2-3781-41C5-E053-F662850AB413","latestVersionIndicator":"Yes","beginDate":"2017-12-14","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-12-14","modifiedBy":"ONEDATA","dateModified":"2017-12-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"605291C2-3792-41C5-E053-F662850AB413","latestVersionIndicator":"Yes","beginDate":"2017-12-14","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-12-14","modifiedBy":"NYCHM","dateModified":"2018-02-12","changeDescription":".","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[{"name":"LYMpost_DS_lym_dis_stat_by_pet","type":"NMDP_FN","context":"NHLBI"}],"ReferenceDocuments":[{"name":"What is the current disease status?","type":"Application Standard Question Text","description":"What is the current disease status?","url":null,"context":"NHLBI"},{"name":"What was the positron emissio","type":"Preferred Question Text","description":"What was the positron emission tomography metabolic lugano lymphoma response disease status?","url":null,"context":"NHLBI"},{"name":"What is the current disease status? (by PET (metabolic) criteria)","type":"Alternate Question Text","description":"What is the current disease status? (by PET (metabolic) criteria)","url":null,"context":"NHLBI"}],"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"6053952E-CA87-6524-E053-F662850AB8CC","latestVersionIndicator":"Yes","beginDate":"2017-12-14","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-12-14","modifiedBy":"NYCHM","dateModified":"2018-02-12","changeDescription":".; System generated def displayed as alt def.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}